Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry (Q38825446)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 April 2017

Language	Label	Description	Also known as
English	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry	scientific article published on 21 April 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

hospitalization

1 reference

based on heuristic

inferred from title

Gian Paolo Fadini

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

7

object named as

Angelo Avogaro

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Saula Vigili de Kreutzenberg

5

object named as

Saula Vigili de Kreutzenberg

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Stefania Saragoni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Pierluigi Russo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Luca Degli Esposti

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mario Melazzini

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

OsMed Health DB Network

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

21 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1416-1424

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Databas

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12979

21 January 2018

Identifiers

10.1111/DOM.12979

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28432754%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38825446&oldid=1903890309"